MXPA04001418A - Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides. - Google Patents

Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.

Info

Publication number
MXPA04001418A
MXPA04001418A MXPA04001418A MXPA04001418A MXPA04001418A MX PA04001418 A MXPA04001418 A MX PA04001418A MX PA04001418 A MXPA04001418 A MX PA04001418A MX PA04001418 A MXPA04001418 A MX PA04001418A MX PA04001418 A MXPA04001418 A MX PA04001418A
Authority
MX
Mexico
Prior art keywords
parathyroid hormone
oral delivery
cnac
delivery agent
hormone fragments
Prior art date
Application number
MXPA04001418A
Other languages
English (en)
Inventor
David Bateman Simon
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA04001418A publication Critical patent/MXPA04001418A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Abstract

Se proporcionan composiciones farmaceuticas para el suministro oral efectivo de una hormona paratiroides, PTH, asi como metodos para la administracion de las composiciones. Ademas, tambien se proporcionan metodos para estimular la formacion de nuevos huesos y/o prevenir osteoporosis.
MXPA04001418A 2001-08-17 2002-08-16 Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides. MXPA04001418A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31304801P 2001-08-17 2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en) 2001-08-17 2002-08-16 5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number Publication Date
MXPA04001418A true MXPA04001418A (es) 2004-05-27

Family

ID=23214149

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001418A MXPA04001418A (es) 2001-08-17 2002-08-16 Acido n-(5-clorosalociloil)-8-aminocaprilico como agente de suministro oral para fragmentos de hormona paratiroides.

Country Status (26)

Country Link
US (4) US20040242478A1 (es)
EP (1) EP1420827B8 (es)
JP (2) JP4959917B2 (es)
KR (1) KR20040030120A (es)
CN (1) CN1279981C (es)
AT (1) ATE443527T1 (es)
AU (1) AU2002333443C1 (es)
BR (1) BRPI0211932B1 (es)
CA (1) CA2453646C (es)
CO (1) CO5560586A2 (es)
CY (1) CY1109661T1 (es)
DE (1) DE60233803D1 (es)
DK (1) DK1420827T3 (es)
EC (1) ECSP044961A (es)
ES (1) ES2333587T3 (es)
HU (1) HUP0401441A3 (es)
IL (2) IL159714A0 (es)
MX (1) MXPA04001418A (es)
NO (1) NO328069B1 (es)
NZ (1) NZ531018A (es)
PL (1) PL210258B1 (es)
PT (1) PT1420827E (es)
RU (1) RU2322256C2 (es)
SI (1) SI1420827T1 (es)
WO (1) WO2003015822A1 (es)
ZA (1) ZA200400242B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101837120A (zh) * 2001-06-01 2010-09-22 诺瓦提斯公司 口服施用甲状旁腺激素和降钙素
NZ531018A (en) * 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
DE60318192T2 (de) * 2002-04-10 2008-04-30 The University Of Virginia Patent Foundation Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PT2316473E (pt) 2003-07-23 2013-09-20 Novartis Ag Utilização de calcitonina na osteoartrite
GB0427600D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8110547B2 (en) * 2005-01-12 2012-02-07 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
EP1896134A2 (en) * 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
EP1937627A4 (en) 2005-09-19 2010-09-01 Emisphere Tech Inc CRYSTALLINE FORMS OF N-(5-CHLOROSALICYLOYL) -8-AMINOCAPRYL ACETATE
GB0522566D0 (en) * 2005-11-04 2005-12-14 Novartis Ag Organic compounds
EP1945245A2 (en) * 2005-11-10 2008-07-23 The Board of Control of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP5042312B2 (ja) * 2006-08-31 2012-10-03 ノバルティス アーゲー Ｈｇｈを含む経口送達用医薬組成物
PL2131810T3 (pl) * 2007-03-02 2011-09-30 Novartis Ag Podawanie doustne kalcytoniny
NZ585080A (en) 2007-11-02 2012-05-25 Emisphere Tech Inc Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
WO2012130193A1 (en) 2011-03-31 2012-10-04 Zentiva, K.S. Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
IL253802B (en) * 2015-02-09 2022-06-01 Entera Bio Ltd A preparation for the treatment of osteoporosis
KR101796604B1 (ko) * 2016-08-30 2017-11-10 목포대학교 산학협력단 위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
EP0618805A1 (en) * 1991-12-17 1994-10-12 PROCTER & GAMBLE PHARMACEUTICALS, INC. Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone
JP3717925B2 (ja) * 1992-09-29 2005-11-16 ネクター セラピューティクス 副甲状腺ホルモンの活性フラグメントの肺導入
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
DK0993831T3 (da) * 1997-02-07 2008-03-25 Emisphere Tech Inc Forbindelser og præparater til tilförsel af aktive stoffer
JP2003533167A (ja) * 1998-11-25 2003-11-11 ザ ゼネラル ホスピタル コーポレーション アミノ末端改変副甲状腺ホルモン（ｐｔｈ）アナログ
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
ES2386263T3 (es) * 2000-03-21 2012-08-14 Emisphere Technologies, Inc. Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
CN101837120A (zh) 2001-06-01 2010-09-22 诺瓦提斯公司 口服施用甲状旁腺激素和降钙素
NZ531018A (en) * 2001-08-17 2006-03-31 Novartis Ag 5-CNAC as oral delivery agent for parathyroid hormone fragments
EP1651248B1 (en) * 2003-07-11 2009-09-09 Novartis AG Orally dosed pharmaceutical compositions comprising a delivery agent in micronized form

Also Published As

Publication number Publication date
CO5560586A2 (es) 2005-09-30
JP2005501852A (ja) 2005-01-20
SI1420827T1 (sl) 2010-01-29
HUP0401441A2 (hu) 2004-12-28
AU2002333443B2 (en) 2006-06-29
RU2322256C2 (ru) 2008-04-20
US20040242478A1 (en) 2004-12-02
US20060217313A1 (en) 2006-09-28
ZA200400242B (en) 2004-11-18
WO2003015822A1 (en) 2003-02-27
CN1279981C (zh) 2006-10-18
EP1420827B8 (en) 2009-12-23
BR0211932A (pt) 2004-10-26
PL365388A1 (en) 2005-01-10
US20120088725A1 (en) 2012-04-12
DE60233803D1 (de) 2009-11-05
ATE443527T1 (de) 2009-10-15
EP1420827A1 (en) 2004-05-26
CN1543357A (zh) 2004-11-03
JP2009242410A (ja) 2009-10-22
AU2002333443C1 (en) 2009-10-08
ES2333587T3 (es) 2010-02-24
JP4959917B2 (ja) 2012-06-27
HUP0401441A3 (en) 2012-09-28
IL159714A (en) 2010-12-30
EP1420827B1 (en) 2009-09-23
BRPI0211932B1 (pt) 2016-12-06
CY1109661T1 (el) 2014-08-13
ECSP044961A (es) 2004-03-23
PT1420827E (pt) 2009-12-15
IL159714A0 (en) 2004-06-20
NO20040598L (no) 2004-02-10
DK1420827T3 (da) 2009-12-21
US9272040B2 (en) 2016-03-01
NO328069B1 (no) 2009-11-23
NZ531018A (en) 2006-03-31
PL210258B1 (pl) 2011-12-30
US20090264367A1 (en) 2009-10-22
RU2004107899A (ru) 2005-05-10
CA2453646C (en) 2008-09-30
CA2453646A1 (en) 2003-02-27
KR20040030120A (ko) 2004-04-08

Similar Documents

Publication Publication Date Title
IL159714A0 (en) 5-cnac as oral delivery agent for parathyroid hormone fragments
MXPA03007837A (es) Composiciones para suministrar bisfosfonatos.
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
IL159996A0 (en) Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient
WO2003047504A3 (en) Prevention and treatment of androgen-deprivation induced osteoporosis
ZA200405657B (en) Formulation & dosage form for the controlled delivery of therapeutic agents.
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
IL175158A0 (en) Tocopherol-modified therapeutic drug compounds
WO2002041837A3 (en) Treatment of mucositis
FR06C0032I1 (es)
GT199700009AA (es) Terapia combinada para la osteoporosis
IL158777A0 (en) Orally administering parathyroid hormone and calcitonin
TW200511999A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
PL370361A1 (en) Alkyl urea retinoid agonists i
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
WO2002074315A8 (de) Pharmazeutische kombinationspräparate enthaltend aromatasehemmer und substanzen mit estrogener wirkung sowie ihre verwendung zur herstellung eines medikaments zur estrogen-ersatz-therapie
PL370459A1 (en) Substituted urea retinoid agonists ii
AU2003286617A8 (en) Calcitonin drug-oligomer conjugates, and uses thereof
MXPA05000978A (es) Formulaciones farmaceuticas novedosas de comienzo rapido que contienen un compuesto para la disfucion sexual que comprenden polvo de cacao y uso de las mismas.
MXPA03006157A (es) Metodo de terapia de reemplazo de hormona y su forma de administracion.
HUP0204258A3 (en) Use of vitamin d-derivatives for preparation of pharmaceutical compositions useful in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
IL125983A0 (en) Pharmaceutical composition comprising factor xiiia
EP1408043A8 (en) 2''oxo-voruscharin and analogues thereof

Legal Events

Date Code Title Description
FG Grant or registration
HH Correction or change in general